Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    85.7%

    Based on 6 completed trials

    Completion Rate
    86%(6/7)
    Active Trials
    0(0%)
    Results Posted
    50%(3 trials)
    Terminated
    1(14%)

    Phase Distribution

    Phase 4
    2
    29%
    Phase 3
    3
    43%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    5

    Late Stage

    Phase Distribution5 total trials
    Phase 3Large-scale testing
    3(60.0%)
    Phase 4Post-market surveillance
    2(40.0%)

    Highest Phase Reached

    Phase 4

    Trial Status & Enrollment

    Completion Rate

    85.7%

    6 of 7 finished

    Non-Completion Rate

    14.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    7

    all time

    Status Distribution
    Completed(6)
    Terminated(1)

    Detailed Status

    Completed6
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    7
    Active
    0
    Success Rate
    85.7%
    Most Advanced
    Phase 4

    Trials by Phase

    Phase 33 (60.0%)
    Phase 42 (40.0%)

    Trials by Status

    completed686%
    terminated114%

    Recent Activity

    0 active trials
    Showing 5 of 7
    completed

    XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

    NCT00676520
    completedphase_3

    SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    NCT00307047
    terminatedphase_4

    SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

    NCT00917163
    completed

    XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

    NCT00631228
    completedphase_3

    SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

    NCT00180479
    View all 7 trials

    Clinical Trials (7)

    Showing 7 of 7 trials
    NCT00676520

    XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

    Completed
    NCT00307047Phase 3

    SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    Completed
    NCT00917163Phase 4

    SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

    Terminated
    NCT00631228

    XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

    Completed
    NCT00180479Phase 3

    SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

    Completed
    NCT00180310Phase 3

    SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    Completed
    NCT00402272Phase 4

    SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe

    Completed

    All 7 trials loaded

    Drug Details

    Intervention Type
    Device
    Total Trials
    7